Faculty of 1000 evaluation for Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with the use of GRADE and implications for practice and research.

Author(s):  
Melvin Chiu
2021 ◽  
Author(s):  
Emily A. Croce ◽  
Fabiana C. P. S. Lopes ◽  
Jennifer Ruth ◽  
Jonathan I. Silverberg

Author(s):  
Carol Stephanie C. Tan‐Lim ◽  
Natasha Ann R. Esteban‐Ipac ◽  
Marysia Stella T. Recto ◽  
Mary Anne R. Castor ◽  
Roxanne J. Casis‐Hao ◽  
...  

2021 ◽  
pp. 120347542199377
Author(s):  
Evan Tang ◽  
Talha Maqbool ◽  
Megan Lam ◽  
Gaelen P. Adam ◽  
Mina Tadrous ◽  
...  

Background Psoriasis and atopic dermatitis are common among older adults (≥65 years old), but clinical trials often exclude that population. Objective To synthesize evidence from observational studies on the safety of systemic therapies (conventional or biologic) for psoriasis and atopic dermatitis among older adults in a systematic review. Methods We searched MEDLINE and EMBASE (inception to October 31, 2019) and included observational studies reporting adverse events among older people treated with systemic therapy for psoriasis or atopic dermatitis. Outcomes were death, hospitalization, emergency department visits, infections, major cardiovascular events, renal toxicity, hepatotoxicity, and cytopenias. We assessed study quality using the Newcastle-Ottawa Scale. Results We included 22 studies on treatment for psoriasis and 2 for atopic dermatitis. Most studies were small and non-comparative and 20 of 24 were low quality. Studies comparing safety between medications or medication classes or between older and younger adults did not show apparent differences but had wide confidence intervals around relative effect estimates. Heterogeneity of study design and reporting precluded quantitative synthesis. Conclusions There is scant evidence on the safety of conventional systemic and biologic medications for older adults with psoriasis or atopic dermatitis; older adults and their clinicians should be aware of this evidence gap.


2018 ◽  
Vol 178 (4) ◽  
pp. 879-888 ◽  
Author(s):  
S.M.D. Ruff ◽  
K.A. Engebretsen ◽  
C. Zachariae ◽  
J.D. Johansen ◽  
J.I. Silverberg ◽  
...  

2018 ◽  
Vol 29 (6) ◽  
pp. 539-541 ◽  
Author(s):  
Yunlei Pan ◽  
Lina Xu ◽  
Jianjun Qiao ◽  
Hong Fang

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Lanlan Zhang ◽  
Lixiu He ◽  
Jin Gong ◽  
Chuntao Liu

Irreversible airway obstruction (IAO) is a subtype of asthma and relates to poorer prognosis in some asthma patients. However, the prevalence and risk factors for IAO are unknown. A systematic review regarding controlled clinical studies (cohort, case-control studies) on IAO asthma in adult and/or children affected by asthma/early wheeze was performed. Eighteen papers were identified in this study. It was reported that the incidence of IAO at random effects or fixed effects in severe asthma and nonsevere asthma was 0.54 (95% CI: 0.45–0.62) and 0.16 (95% CI: 0.12–0.20), respectively. In IAO asthma, the pooled odds ratio (OR) related to smoking exposure was 2.22 (95% CI: 1.82–2.73), the OR for male, smoking, and fractional exhaled nitric oxide (FENO) was 2.22 (95% CI: 1.82–2.7), 1.79 (95% CI: 1.46–2.19), and 2.16 (95% CI: 1.05–4.43), respectively, suggesting these factors increase the risk of IAO. However, a decreased OR in IAO asthma was observed due to rhinitis (OR = 0.31, 95% CI: 0.24–0.40), atopy (OR = 0.584, 95% CI: 0.466–0.732), and atopic dermatitis (OR = 0.60, 95% CI: 0.42–0.85), indicating these factors are associated with reduced risk of IAO. IAO in asthma is associated with gender, smoking, FENO, rhinitis, atopy, and atopic dermatitis.


Sign in / Sign up

Export Citation Format

Share Document